<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362333">
  <stage>Registered</stage>
  <submitdate>5/04/2012</submitdate>
  <approvaldate>5/04/2012</approvaldate>
  <actrnumber>ACTRN12612000393853</actrnumber>
  <trial_identification>
    <studytitle>High Concentration Oxygen in Neuromuscular Disease</studytitle>
    <scientifictitle>Response of Patients with Neuromuscular Disease to Hyperoxia and Normoxia, as Measured by Carbon Dioxide Levels</scientifictitle>
    <utrn>U1111-1129-6717</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuromuscular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>50% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.</interventions>
    <comparator>21% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>10 and 20 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minute ventilation, adjusted for baseline, calculated using a flow sensor attached to the expiratory port of the participant's mask.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of dead space to tidal volume ratio, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in transcutaneous carbon dioxide greater than or equal to 4mmHg, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in transcutaneous carbon dioxide greater than or equal to 10mmHg, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tidal volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of dead space, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar minute ventilation, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oxygen saturations, adjusted for baseline, as recorded on the TOSCA via continuous electronic recording data download.</outcome>
      <timepoint>Continuously over the time course of the intervention and washout period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of baseline transcutaneous carbon dioxide, as recoded on the TOSCA, on outcome.</outcome>
      <timepoint>Value from baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate, adjusted for baseline, as recoded on the TOSCA.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory rate, adjusted for baseline, measured from capnography equipment.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of neuromuscular disease with a greater than or equal to 10% drop in vital capacity from standing to lying, or a sniff nasal inspiratory pressure under the lower limit (above which lie 95% of healthy subjects), based on work by Uldry and Fitting (Thorax 1995;50(4)).

OR

Kyphoscoliosis with an FVC &lt;65% predicted.</inclusivecriteria>
    <inclusiveminage>14</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Baseline transcutaneous carbon dioxide of greater than or equal to 60mmHg Diagnosis of chronic obstructive pulmonary disease FEV1:FVC ratio less than or equal to 70% (if participant able to perform forced spirometry) Obesity (with a body mass index of greater than or equal to 40) Any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following explaination of the trial and consent, participants will be assessed for eligibility. If eligible, participants will be randomised to the order of interventions (21% oxygen and 50% oxygen). This order will be available to an investigator who is not administering treatment, assessing outcomes or analysing data. Their role is to make available the gas bottles and bags (containing either 21% or 50% oxygen) in the randomised order. The labels on the bottles will be covered to maintain the blinding of other investigators and the participant.</concealment>
    <sequence>By computer.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>18/04/2012</anticipatedstartdate>
    <actualstartdate>13/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/01/2015</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Janine Pilcher</primarysponsorname>
    <primarysponsoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Level 3- ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland, 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Medical Research Institute of New Zealand</fundingname>
      <fundingaddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Richard Beasley</sponsorname>
      <sponsoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Hamish Collie</othercollaboratorname>
      <othercollaboratoraddress>Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Kyle Perrin</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Pip Shirtcliffe</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mitesh Patel</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mathew Williams</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mark Weatherall</othercollaboratorname>
      <othercollaboratoraddress>Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Irene Braithewaite</othercollaboratorname>
      <othercollaboratoraddress>Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Oxygen therapy has been shown to increase carbon dioxide in the blood of patients with certain respiratory conditions. This study aims to find out if oxygen therapy increases carbon dioxide levels in patients with neuromuscular disease and, if so, how.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee: Central</ethicname>
      <ethicaddress>1 The Terrace, Wellington, 6011</ethicaddress>
      <ethicapprovaldate>30/03/2012</ethicapprovaldate>
      <hrec>CEN/11/11/065</hrec>
      <ethicsubmitdate>11/10/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellinton Regional Hospital, Riddiford Street, Newtown, Wellington 6021  </address>
      <phone>+64 4 8050241  </phone>
      <fax />
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>